Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Glycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL15463836 | 1.00 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL5690684 | 1.00 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL5903143 | 0.94 | LMNA (0.50) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL1792710 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL6662558 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL28918498 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL1134753 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL2487171 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL5161896 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 | |
| Glycerin SCHEMBL468638 | 0.94 | LMNA (0.56) | LMNAALDH1A1SMN1; SMN2THRBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4432862-A1 | ORAL PRODUCTS WITH NICOTINE-POLYMER COMPLEX | Nicoventures Trading Limited (GB) | 2024-09-25 | — | — | EP | claimed |
| EP-4188338-A1 | BILAYER TABLET COMPRISING EZETIMIBE AND ATORVASTATIN | KRKA, d.d., Novo mesto (SI) | 2023-06-07 | — | — | EP | claimed |
| WO-2023084498-A1 | ORAL PRODUCTS WITH NICOTINE-POLYMER COMPLEX | Nicoventures Trading Limited (GB) | 2023-05-19 | — | — | WO | claimed |
| US-20230148652-A1 | ORAL PRODUCTS WITH NICOTINE-POLYMER COMPLEX | NICOVENTURES TRADING LTD (GB) | 2023-05-18 | — | — | US | claimed |
| WO-2022023206-A1 | BILAYER TABLET COMPRISING EZETIMIBE AND ATORVASTATIN | KRKA, D.D., NOVO MESTO (SI) | 2022-02-03 | — | — | WO | claimed |
| WO-2020139237-A2 | A BILAYER TABLET FORMULATION OF ATORVASTATIN CALCIUM AND EZETIMIBE | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2020-07-02 | — | — | WO | claimed |
| CN-109688841-A | The preparation method of alimentation composition | 雀巢产品技术援助有限公司 | 2019-04-26 | — | — | CN | claimed |
| US-20180311298-A1 | Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated With Individuals Suffering from Alcohol Intoxication | BURN-OFF, LLC | 2018-11-01 | — | — | US | claimed |
| CN-108516988-A | A kind of new technique for synthesizing of toothpaste additive calcium glycerophosphate | 扬州工业职业技术学院 | 2018-09-11 | — | — | CN | claimed |
| WO-2018146302-A1 | PHARMACEUTICAL BILAYER TABLET COMPOSITION OF ATORVASTATIN CALCIUM AND EZETIMIBE | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2018-08-16 | — | — | WO | claimed |
| US-20060275223-A1 | Erythritol compositions for teeth and gums | XLEAR, INC. | 2006-12-07 | — | — | US | claimed |
| EP-1233677-B1 | SLOW MELTING COATING FOR ICE CONFECTIONS | NESTLE SA (CH) | 2005-06-08 | — | — | EP | claimed |
| WO-2004098294-A1 | DOUGH ADDITIVE | BRECHET & RICHTER COMPANY (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1171085-B1 | ORAL CARE COMPOSITION | UNILEVER NV (NL) | 2004-08-18 | — | — | EP | claimed |
| EP-1125575-B1 | PERFUSATE PREPARATION FOR OPHTHALMIC OPERATION | OPHTECS CORP (JP) | 2004-03-03 | — | — | EP | claimed |
| US-20030180414-A1 | Method of controlling release of bitterness inhibitors in chewing gum and gum produced thereby | WM. WRIGLEY JR. COMPANY | 2003-09-25 | — | — | US | claimed |
| EP-1123081-B1 | HARDENABLE CERAMIC HYDRAULIC CEMENT | SYNTHES AG (CH) | 2002-12-11 | — | — | EP | claimed |
| EP-1051086-B1 | DIETETIC COMPOSITION IN THE FORM OF A SUBSTITUTION SALT FOR TABLE SALT | SANOFI SYNTHELABO (FR) | 2002-04-17 | — | — | EP | claimed |
| EP-0681833-B1 | Nasally administrable compositions | DOTT RES LAB (JP) | 2001-06-13 | — | — | EP | claimed |
| EP-0719148-B1 | ORAL WATER SOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRONE DERIVATIVE AND CALCIUM SALT | DEGHENGHI ROMANO (CH) | 1998-02-18 | — | — | EP | claimed |